Actively Recruiting
Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-07-18
1000
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the current use and factors affecting Bruton's Tyrosine Kinase inhibitor (BTKi) treatment in patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) in China. This observational study aims to understand treatment patterns, including efficacy, safety, switches between different BTKis, and time-limited BTKi therapies to explore better treatment approaches for these patients. The study observes patients who have received BTKi treatment such as Orelabrutinib, Ibrutinib, Zanubrutinib, or Acalabrutinib between February 2023 and February 2024. It collects real-world data from multiple centers to analyze the current treatment landscape and factors influencing therapy decisions without administering interventions. Participants' characteristics, overall response rates, and incidence of adverse reactions are evaluated over up to one year. Data is gathered retrospectively from medical records, focusing on BTKi treatments. The study’s duration spans from July 2024 to July 2025, with ongoing monitoring of treatment outcomes and safety profiles to better inform future therapeutic strategies.
CONDITIONS
Brief Title
Current Status of BTKi Treatment for CLL/SLL in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 18 years
- Patients with a confirmed diagnosis of CLL/SLL
- Received BTK inhibitor treatment between February 2023 and February 2024
You will not qualify if you...
- Patients with other types of lymphoma
- Cases deemed unsuitable for inclusion in this study by the investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 year
Participants who have received BTK inhibitor treatment for CLL/SLL are observed to assess treatment status and related factors including efficacy and safety.
Trial Site Locations
Total: 1 location
1
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, China, 210029
Actively Recruiting
Research Team
H
Huayuan Zhu, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here